United States · 
What does Aperture Venture Partners invest in?
Aperture Venture Partners invests most often at Series C and Series B (57% of the rounds on record), in sectors such as Medical Device, Pharmaceutical and Healthcare IT.
Aperture Venture Partners highlights
- 01
24 rounds on record
- 02
Mostly Series C and Series B: 57% of its rounds
- 03
3 exits from the portfolio
What they do
Aperture Venture Partners is a healthcare-focused investment firm.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- GrowthSeedSeries ASeries B
- Sectors
- Medical DevicePharmaceuticalHealthcare IT
- Based in
- New York, United States
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first24 appearances
- 2024
1 round
- Oct
- 2019
1 round
- Oct
- 2016
1 round
- Jul
- 2015
5 rounds
- Sept
- Aug
- Apr
- Mar
- Mar
- 2014
2 rounds
- May
- Apr
- 2013
4 rounds
- Dec
- Sept
- May
- Mar
- 2012
1 round
- Jun
- 2011
3 rounds
- Aug
- Jul
- Apr
- 2009
1 round
- Oct
- 2007
2 rounds
- Feb
- Jan
- 2004
2 rounds
- Jul
- Mar
- 2003
1 round
- Nov
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration1 named
EHEric Holden SillmanMemberiForm ADV
We also hold 3 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$81Mgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
- Legal name
- Aperture Management LLC
- SEC number
- CRD 162665
Exits from the portfolio
Companies it backed that were later bought or listed3 in all
MAKO SurgicalBought by Stryker Corporation$1.6BSept 2013
Ceptaris TherapeuticsBought by Actelion Pharmaceuticals$250MJul 2013
Ception TherapeuticsBought by Cephalon$250MFeb 2010
An exit counts when it came after the firm's first round in the company. From historical deal records.